JP2022525925A5 - - Google Patents

Info

Publication number
JP2022525925A5
JP2022525925A5 JP2021556481A JP2021556481A JP2022525925A5 JP 2022525925 A5 JP2022525925 A5 JP 2022525925A5 JP 2021556481 A JP2021556481 A JP 2021556481A JP 2021556481 A JP2021556481 A JP 2021556481A JP 2022525925 A5 JP2022525925 A5 JP 2022525925A5
Authority
JP
Japan
Prior art keywords
tcr
modified
chain
functional fragment
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021556481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525925A (ja
JP7680032B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000140 external-priority patent/WO2020188348A2/en
Publication of JP2022525925A publication Critical patent/JP2022525925A/ja
Publication of JP2022525925A5 publication Critical patent/JP2022525925A5/ja
Application granted granted Critical
Publication of JP7680032B2 publication Critical patent/JP7680032B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021556481A 2019-03-18 2020-03-17 A2/ny-eso-1特異的t細胞受容体およびその使用 Active JP7680032B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819988P 2019-03-18 2019-03-18
US62/819,988 2019-03-18
PCT/IB2020/000140 WO2020188348A2 (en) 2019-03-18 2020-03-17 A2/ny-eso-1 specific t cell receptors and uses thereof

Publications (3)

Publication Number Publication Date
JP2022525925A JP2022525925A (ja) 2022-05-20
JP2022525925A5 true JP2022525925A5 (enExample) 2023-03-17
JP7680032B2 JP7680032B2 (ja) 2025-05-20

Family

ID=70465122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556481A Active JP7680032B2 (ja) 2019-03-18 2020-03-17 A2/ny-eso-1特異的t細胞受容体およびその使用

Country Status (6)

Country Link
US (2) US12473346B2 (enExample)
EP (1) EP3941939A2 (enExample)
JP (1) JP7680032B2 (enExample)
CN (1) CN113906140B (enExample)
AU (1) AU2020243431B2 (enExample)
WO (1) WO2020188348A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN116420076A (zh) * 2020-09-27 2023-07-11 基因泰克公司 高通量多参数免疫细胞接合物筛选测定
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
US20240207319A1 (en) 2021-05-06 2024-06-27 Ludwig Institute For Cancer Research Ltd Compositions and methods for immunotherapy
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
EP4374872A1 (en) * 2022-11-22 2024-05-29 Koninklijke Philips N.V. Pde enhanced car-t cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078334A1 (en) 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
NZ550815A (en) 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
WO2005113595A2 (en) 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディとその使用
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2008039818A2 (en) * 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
WO2008037943A1 (en) 2006-09-29 2008-04-03 Medigene Limited Cells transformed with nucleic acid encoding ny-eso t cell receptors
CA2700278A1 (en) 2007-09-25 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Modified t cell receptors and related materials and methods
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
IL298125A (en) 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
KR102546296B1 (ko) 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
EP3377523A4 (en) * 2015-11-19 2019-06-19 The Regents of The University of California CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
CN108456247A (zh) 2017-02-20 2018-08-28 上海恒润达生生物科技有限公司 靶向ny-eso-1的t细胞受体及其用途

Similar Documents

Publication Publication Date Title
CN110818802B (zh) 一种嵌合t细胞受体star及其应用
CN106459990B (zh) 三功能t细胞抗原偶联物及其制备方法和用途
CN109575143B (zh) 双特异性cd20-cd19-car及其应用
CN113698490B (zh) 靶向cea的缺氧诱导启动的car结构及免疫细胞和应用
JP2023052263A (ja) 腫瘍形質導入のための組成物及び方法
US11878035B2 (en) T cell-antigen coupler with various construct optimizations
CN110616191B (zh) 共刺激配体联合的car t疗法
KR102316091B1 (ko) Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도
JP7404279B2 (ja) 様々な構築物最適化を備えたt細胞抗原カプラ
CN110357952B (zh) 识别人乳头瘤病毒hpv16-e7抗原的tcr
CN108138148A (zh) T细胞的激活和扩增
JP2022521183A5 (enExample)
WO2024119769A9 (zh) 增强向肿瘤部位浸润能力的car-nk细胞制备及应用
CN111019905A (zh) Car修饰细胞及其在制备自身免疫性疾病药物中的应用
JP2021501567A (ja) Y182t突然変異を有するt細胞−抗原カプラおよびその方法ならびに使用
JP2023528255A5 (enExample)
CN103965362A (zh) 一种可使t细胞趋向肿瘤部位的嵌合趋化因子受体
CN114555815A (zh) T细胞受体及其使用方法
WO2023010068A2 (en) Multiprotein-engineered cells secreting a multispecific antibody
WO2021190551A1 (zh) 结合cd19的嵌合抗原受体及其用途
KR20220038776A (ko) T 세포 수용체 및 이의 사용 방법
KR20220040489A (ko) T 세포 수용체 및 이의 사용 방법
CN111499766B (zh) 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用
CN116490518A (zh) 用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法
CN113929767B (zh) 具有高亲和力的t细胞受体及其用途